Researchers Report Novel A-beta Derived Peptide Biomarkers Strongly Indicated for Early Diagnosis, Prognosis and Treatment Monit
July 19 2004 - 10:00AM
PR Newswire (US)
Researchers Report Novel A-beta Derived Peptide Biomarkers Strongly
Indicated for Early Diagnosis, Prognosis and Treatment Monitoring
of Alzheimer's Disease Ciphergen SELDI-based Immunoassay Reveals
New Peptide Variants in Clinical AD Samples FREMONT, Calif., July
19 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc.
(NASDAQ:CIPH) announced today that three separate studies involving
a SELDI ProteinChip(R) Amyloid Beta (A-beta) Multi-Peptide
Immunoassay were presented during a biomarkers symposium on day 2
of the 9th International Conference on Alzheimer's Disease (ICAD)
in Philadelphia which runs from July 17-22. The first study
presented by Dr. Nicolas Sergeant from INSERM in France entitled
"Amino-truncated A-beta 42 species as early diagnostic and
etiological biomarkers of Alzheimer's disease" described using a
SELDI immunoassay to evaluate the presence of N-terminally
truncated Abeta42 peptides in patient cerebrospinal fluid (CSF).
The accompanying abstract states "Abeta42 peptides were clearly
present in AD patients, strongly indicating that they are valuable
biomarkers for early diagnosis and prognosis of AD." In the second
study, "Neuroproteomic Profiling of Amyloid beta Peptides in human
CSF with SELDI-TOF MS," Prof. Jens Wiltfang from the Center of
Clinical Neuroproteomics, Erlangen, Germany, described using the
SELDI assay to discover three novel A-Beta peptides in clinical CSF
samples. Prof. Wiltfang stated that the ratio of the novel peptides
as measured by SELDI separated patients and controls even more
precisely than the gold standard ratio of Ab1-42/1-40 in the
clinical samples tested. The third study presented by Dr. Douglas
Galasko from University of California San Diego on "Measuring
candidate proteins in the context of AD clinical trials" showed
reproducible, quantitative changes in the concentration of clinical
CSF A-beta peptide variants in response to treatment with
non-steroidal anti-inflammatory drug compounds. Martin Verhoef,
President of Ciphergen's Biosystems Division, stated "These
positive results were achieved some time ago with our ProteinChip
System IIc. Using our new ProteinChip System, Series 4000, we have
achieved improved sensitivity and quantitation of A-beta making the
Series 4000 an excellent multi-marker, immunoassay platform for
A-beta peptide variants described in this work." A-beta peptide is
the main constituent of senile plaques found in the brains of AD
patients and a key molecule in the disease pathogenesis. Reliable
methods to detect and quantify soluble forms of this peptide in
human biological fluids and model systems are of great importance
for both clinical diagnosis and understanding disease mechanisms.
The SELDI platform enables researchers to rapidly monitor multiple
forms of A-beta from small volumes of sample using a single
antibodybased assay, offering unique advantages over ELISA or gel
based methods. There are a growing number of Alzheimer's
researchers now using this assay in both clinical and basic
research. Go to http://www.ciphergen.com/pub/ to find a growing
list of over 20 publications involving the SELDI A-Beta
Immunoassay. About Ciphergen Ciphergen's Biosystems Division
develops, manufactures and markets a family of ProteinChip(R)
Systems and services for clinical, research, and process proteomics
applications, as well as a broad range of bioseparations media for
protein purification and large scale production. ProteinChip
Systems enable protein discovery, characterization, identification
and assay development to provide researchers with predictive,
multi-marker assay capabilities and a better understanding of
biological function at the protein level. Ciphergen's Diagnostics
Division is dedicated to the discovery of protein biomarkers and
panels of biomarkers and their development into protein molecular
diagnostic tests that improve patient care; and to providing
collaborative R&D services through its Biomarker Discovery
Center(R) laboratories for biomarker discovery for new diagnostic
tests as well as pharmacoproteomic services for improved drug
toxicology, efficacy and theranostic assays. Additional information
about Ciphergen can be found at http://www.ciphergen.com/. Safe
Harbor Statement Note Regarding Forward-Looking Statements: For
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"), Ciphergen disclaims any intent or obligation to update
these forward-looking statements, and claims the protection of the
Safe Harbor for forward-looking statements contained in the Act.
Examples of such forward-looking statements include statements
regarding the use of ProteinChip technology to discover useful
protein biomarkers that can act as novel drug targets or disease
markers, develop and commercialize clinical diagnostics that
improve patient care, the ability to provide services that lead to
improved toxicology assays and diagnostic assays, and statements
regarding our Diagnostics Division. Actual results may differ
materially from those projected in such forward-looking statements
due to various factors, including the ProteinChip technology's
ability to validate and/or develop protein biomarkers as novel drug
targets, diagnostic or toxicology assays, and the Company's ability
to successfully commercialize such tests. Investors should consult
Ciphergen's filings with the Securities and Exchange Commission,
including its Form 10-Q dated May 10, 2004 as amended May 20, 2004,
for further information regarding these and other risks of the
Company's business. NOTE: Ciphergen, ProteinChip, Biomarker
Discovery Center and BioSepra are registered trademarks of
Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc.
CONTACT: Sue Carruthers, Investor Relations, of Ciphergen
Biosystems, Inc., +1-510-505-2297 Web site:
http://www.ciphergen.com/pub Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024